Slaughter and May advised Credit Suisse (Hong Kong) Limited on the HK$1.27 billion secondary block trade of shares in Genscript Biotech Corporation

Slaughter and May, Hong Kong, advised Credit Suisse (Hong Kong) Limited, as manager, in relation to the HK$1.27 billion secondary placing of shares in Genscript Biotech Corporation held by KPCB China Fund, L.P. and KPCB China Founders Fund, L.P. The placing represents approximately 2.6% of the issued share capital of Genscript Biotech Corporation.

Genscript Biotech Corporation is a leading biotech company focusing exclusively on early drug discovery and development services and is listed on the Main Board of the Stock Exchange of Hong Kong Limited.